Literature DB >> 15026347

Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen.

Victor I Romanov1, Terry Whyard, Howard L Adler, Wayne C Waltzer, Stanley Zucker.   

Abstract

Bone metastasis is the most frequent complication of prostate cancer (PC). Elucidation of the biological basis of this specificity is required for the development of approaches for metastatic inhibition. We investigated the possibility that the preferential attachment of PC cells to bone marrow endothelium (as opposed to endothelium from other organs) affects this specificity. We selected, from peptide phage-displayed libraries, peptide ligands to surfaces of PC cells (C4-2B) attenuated (30-40%) binding of C4-2B cells to bone marrow endothelial cells (BMECs). We then determined the molecules on the surface of C4-2B cells interacted with the selected peptides using column affinity chromatography and a cDNA expression phage-displayed library generated from C4-2B cells in T7 phage. We identified a phage from the cDNA library that specifically bound to one of the selected peptides-L11. This phage displayed the amino acid sequence homologous for the COOH-terminal portion of prostate-specific antigen (PSA). To examine the possible direct involvement of PSA in the interactions between PC and BMECs, we performed a cell-cell adhesion assay. Antibodies to PSA attenuated PC cells adhesion to BMECs. In addition, exogenous proteolytically active PSA modulated this adhesion. Finally, inactivation of mRNA coding PSA by a small interfering RNA (siRNA) diminished C4-2B cell adhesion to BMECs. These results indicate that PSA expressed as secreted and surface-associated molecules in C4-2B cells is involved in cell-cell interactions and/or digests components of bone marrow endothelium for preferential adhesion and penetration of PC cells. The suggested experimental approach is a promising strategy for identification of cell surface molecules involved in intercellular interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026347     DOI: 10.1158/0008-5472.can-03-3487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  In silico functional profiling of individual prostate cancer tumors: many genes, few functions.

Authors:  Ivan P Gorlov; Jinyoung Byun; Christopher J Logothetis
Journal:  Cancer Genomics Proteomics       Date:  2012 May-Jun       Impact factor: 4.069

2.  Landscape Phage as a Molecular Recognition Interface for Detection Devices.

Authors:  Valery A Petrenko
Journal:  Microelectronics J       Date:  2008-02

Review 3.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

4.  Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.

Authors:  Charles J Dimitroff; Leyla Descheny; Natalia Trujillo; Robert Kim; Vuong Nguyen; Wei Huang; Kenneth J Pienta; Jeffery L Kutok; Mark A Rubin
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

Review 6.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

7.  Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line.

Authors:  Hong Yin; Hanna S Radomska; Daniel G Tenen; Jonathan Glass
Journal:  BMC Cancer       Date:  2006-06-14       Impact factor: 4.430

Review 8.  Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Authors:  Atsushi Mizokami; Kouji Izumi; Hiroyuki Konaka; Yasuhide Kitagawa; Yoshifumi Kadono; Kazutaka Narimoto; Takahiro Nohara; Amit K Bahl; Mikio Namiki
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

9.  Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.

Authors:  Henrique B da Silva; Eduardo P Amaral; Eduardo L Nolasco; Nathalia C de Victo; Rodrigo Atique; Carina C Jank; Valesca Anschau; Luiz F Zerbini; Ricardo G Correa
Journal:  Prostate Cancer       Date:  2013-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.